IQUIR   05412
INSTITUTO DE QUIMICA ROSARIO
Unidad Ejecutora - UE
congresos y reuniones científicas
Título:
DEVELOPMENT OF PEDIATRIC LIQUID DOSAGE FORMS OF BENZNIDAZOLE FOR CHAGAS DISEASE. IN VITRO/IN VIVO STUDIES
Autor/es:
SALOMON, C.J.; LAMAS, M.C.; MANARIN, R; BOTTASO, E.; SERRA E.; REVELLI, S.
Lugar:
Barcelona, España
Reunión:
Congreso; 6th World Meeting on Pharmaceutics, Biopharmaceutics and Pharmaceutical Technology; 2008
Institución organizadora:
APV
Resumen:
Chagas’ disease, a protozoan infection caused by Tripanosoma cruzi, constitutes a major public health problem for developing nations. Congenital transmission has become more relevant as a consequence of the advances in the control of vectorial transmission. In this sense, some countries have specific strategies to deal with this kind of transmission. According to the World Health Organization, 18 to 20 million people in South and Central America and 50,000–100,000 in the United State are infected with Trypanosoma (Schizotrypanum) cruzi, while nearly 90 million persons live in zones where Chagas disease is endemic. Recent surveys indicate that there are 200,000 new cases and 21,000 deaths associated with this condition every year. In addition, approximately 2.800.000 would be children or babies and another 40 million are at risk of acquiring the disease. In Latin America, the morbidity and mortality associated with Chagas’ disease are more than one order of magnitude higher than those caused by malaria, schistosomiasis or leishmaniasis. One of the drugs most frequently used for the treatment of Chagas disease is Benznidazole (BZL) (1), available only in one fixed dose (tablet of 100 mg). Despite of it is the only treatment for Chagas, it is not adequate for most of the pediatric population. In this context, a research priority should be the development of alternative dosage forms with flexible doses and therefore adaptable to the various weights of children treated.